ArticleBritish journal of clinical pharmacology2026
Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results.Age and ageing · 2026Trial
- Article
- Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsCannabidiol (CBD), the main non-intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP-mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol, two commonly used analgesics.
methodsThis was an open-label, fixed-sequence, 2-way crossover study in 13 healthy participants. On Day 1, 25 mg amitriptyline and 50 mg tramadol were co-administered orally in a fasted condition, followed by a 7-day washout period. On Day 8, 30 mg CBD was administered orally 1 h prior to amitriptyline and tramadol. Pharmacokinetic sampling was performed for CBD, amitriptyline, tramadol and their respective active metabolites nortriptyline and O-desmethyltramadol for up to 24 h post-dose. The areas under the curve (AUCs) were compared between visits using a mixed effects model.
resultsTwelve participants (4M/8F) completed the study; one participant (M) dropped out for personal reasons. CBD significantly increased the AUC
conclusionsA single dose of 30 mg CBD significantly influenced the metabolism of amitriptyline in healthy volunteers. In patients, CBD-induced drug interactions may be more pronounced in chronic dosing and dependent upon prandial status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.